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Introduction
Cancer cell invasion and metastasis are multistep
processes that require coordinated series of anti-adhe-
sive, adhesive, migratory, and proteolytic events. Major
proteases involved in these tumor cell-associated
processes are matrix metalloproteinases (MMPs), cys-
teine proteases (e.g. cathepsin B and L), and serine pro-
teases [e.g. the urokinase-type plasminogen activator
(uPA)/plasmin system]. These proteolytic systems also
interact and thereby efficiently activate each other. This
may result in detachment of cancer cells from the primary
tumor, followed by migration through the extracellular
matrix, intra- and extravasation, and eventually metasta-
sis formation in distant organs (Magdolen et al., 2000).
Already in the 1970’s, Reich and his collaborators
showed that increased secretion of plasminogen activa-
tor (PA) by tumor cells is largely responsible for enhanced
extracellular proteolytic activity associated with malig-
nancies (Reich, 1978). Following this early observation, a
number of subsequent studies reported on the correla-
tion between elevated levels of uPA in primary tumor and
cancer progression. In a variety of malignancies, uPA
antigen emerged as a strong, independent, statistically
significant prognostic factor for both disease-free and
overall survival. Increased expression of the uPA receptor
(uPAR) and of the plasminogen activator inhibitor type-1
(PAI-1) in the primary tumor also correlates with a highly
invasive phenotype and poor prognosis of several tumor
types (for reviews see Andreasen et al., 1997; Reuning
et al., 1998; Schmitt et al., 2000; Muehlenweg et al.,
2001). 
Accumulation of the proteolytic activity at the leading
edge of a tumor is an essential feature to allow tissue in-
vasion of many tumor cells. Moreover, binding of uPA to
its receptor activates cell migration via induction of
chemotaxis and regulation of cell adhesion, and has a
stimulatory effect on cell proliferation both directly,
through the activation of cell-signaling pathways, and in-
directly, e.g. via the activation of latent forms of growth
factors by plasmin (Reuning et al., 1998; Andreasen et al.,
2000). Furthermore, there is also some evidence for an in-
volvement of the uPA-system in vascular remodeling
(Rabbani and Mazar, 2001). 
Another group of proteolytic enzymes that plays an es-
sential role in tumor progression is the matrix metallopro-
teinase (MMP) family (Stamenkovic, 2000). These pro-
teases collectively degrade structural components of the
extracellular matrix and of basement membranes, allow-
ing tumor cells to invade the surrounding connective tis-
sue, to enter and exit from blood and lymphatic vessels,
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Serine proteases, cysteine proteases, and matrix
metalloproteinases (MMPs) are involved in cancer cell
invasion and metastasis. Recently, a recombinant bi-
functional inhibitor (chCys-uPA19 – 31) directed against
cysteine proteases and the urokinase-type plasmino-
gen activator (uPA)/plasmin serine protease system
was generated by introducing the uPA receptor
(uPAR)-binding site of uPA into chicken cystatin
(chCysWT). In the present study, we designed and re-
combinantly produced multifunctional inhibitors also
targeting MMPs. The inhibitors comprise the N-termi-
nal inhibitory domain of human TIMP-1 (tissue in-
hibitor of matrix metalloproteinase-1) or TIMP-3,
fused to chCys-uPA19 – 31 or chCysWT. As demonstrat-
ed by various techniques, these fusion proteins effec-
tively interfere with all three targeted protease sys-
tems. In in vitro Matrigel invasion assays, the addition
of recombinant inhibitors strongly reduced invasion
of ovarian cancer cells (OV-MZ-6#8). Additionally, OV-
MZ-6#8 cells were stably transfected with expression
plasmids encoding the various inhibitors. Synthesis
and secretion of the inhibitors was verified by a newly
developed ELISA, which selectively detects the re-
combinant proteins. Invasive capacity of inhibitor-
producing cells was significantly reduced compared
to vector-transfected control cells. Thus, these novel,
compact, and small-size inhibitors directed against
up to three different tumor-associated proteolytic
systems may represent promising agents for preven-
tion of tumor cell migration and metastasis.
Key words: Cysteine protease /Serine protease /Matrix
metalloproteinase /Tumor invasion /Urokinase receptor.
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and thus to metastasize distant organs. Depending on
the nature of MMP and available substrate, MMPs can
also modulate cell proliferation, adhesion, and migration.
A positive correlation between MMP expression and tu-
mor cell invasion and metastasis was demonstrated in
vitro as well as in vivo. A variety of studies showed the as-
sociation of MMPs with the invasive and metastatic be-
havior of virtually all cancer types (for reviews see Curran
and Murray, 1999; Stetler-Stevenson, 2001).
Cathepsin B, H and L, which are primarily lysosomal
cysteine proteases, are also extracellularly present in ele-
vated amounts in different types of tumors and are – to-
gether with the uPA/plasmin system and metallopro-
teinases – involved in cancer invasion by degrading
certain extracellular matrix components. In addition to
this function, cathepsins may activate precursors of oth-
er proteases (Magdolen et al., 2000). A number of reports
have indicated that the balance between cysteine pro-
teases and their endogenous inhibitors is changed in tu-
mors. Moreover, in several clinical studies cathepsins
and their inhibitors were shown to have a high prognostic
impact to predict survival of patients with different tumor
diseases (Lah and Kos, 1998).
In view of their important role in tumor invasion and
metastasis, the uPAR/uPA/plasmin system, MMPs, and
cysteine proteases have become promising therapeutic
targets for development of novel anti-tumor drugs. In
many studies, peptide and small molecule antagonists
were used to block uPA/uPAR-interaction and showed
their effectiveness to reduce cancer cell invasion and
metastasis both in vitro and in vivo (Fong et al., 2002;
Ploug et al., 2002; Schmiedeberg et al., 2002; Sato et al.,
2002). Other approaches include down-regulation of
uPAR expression using antisense gene therapy and inhi-
bition of the proteolytic activity of uPA by synthetic ac-
tive-site inhibitors (Mazar, 2001; Sperl et al., 2001). Also,
targeting of MMPs with their natural inhibitors, the tissue
inhibibitors of matrix metalloproteinases (TIMPs), or syn-
thetic metalloproteinase inhibitors impeded invasion,
subsequent metastasis formation, and tumor-associated
angiogenesis in different in vitro and in vivo models.
These results led to the development of new anti-tumor
drugs, currently tested in clinical trials (Stetler-Steven-
son, 2001; Coussens et al., 2002). Cystatin C is the
strongest human inhibitor of extracellularly released cys-
teine proteases, it was therefore most frequently investi-
gated in tumor invasion and metastasis. Transfection of
tumor cells with cystatin C cDNA led to an inhibition of tu-
mor cell invasion through an artificial matrix barrier in vit-
ro and to a significant reduction of the number of lung
metastases after tail vein injection in nude mice (for a re-
view see Magdolen et al., 2002).
Since these proteolytic systems play an important
role in tumor progression and to some extent display
overlapping, redundant activities, it seems to be an in-
teresting strategy to modulate their proteolytic activity
simultaneously. Recently, bifunctional inhibitors were
designed, which on the one hand are directed against
the enzymatic activity of cysteine proteases, and on the
other hand inhibit binding of the serine protease uPA to
its receptor (uPAR) (Muehlenweg et al., 2000). In the
present study, we extended our concept by designing
bi- and trifunctional inhibitors that are also directed
against MMPs. These recombinant inhibitors were bio-
chemically analyzed with respect to their inhibitory ac-
tivity against MMPs, cysteine proteases, uPA/uPAR-in-
teraction, and in vitro invasion of human ovarian cancer
OV-MZ-6#8 cells. We also generated OV-MZ-6#8 cell
lines which were stably transfected with expression
plasmids encoding bi- or trifunctional inhibitors and test-
ed the effects of the endogenously produced and se-
creted recombinant inhibitors on the invasive capacity of
the cancer cells.
Results
Expression, Purification and Refolding of
Multifunctional Inhibitors
Bifunctional inhibitor molecules were designed which are
composed of the inhibitory domains of human TIMP-1 or
TIMP-3 (N-hTIMP-1 or -3) fused to chicken wild-type
cystatin (chCysWT) and are thus directed against both
matrix metalloproteinases and cysteine proteases. Addi-
tionally, trifunctional inhibitors were generated, in which a
cystatin variant was used that harbors the uPAR-binding
site of the uPA molecule (uPA19 – 31) and blocks
uPA/uPAR-interaction (Muehlenweg et al., 2000). As an
example, the structure of the trifunctional inhibitor N-
hTIMP-1-chCys-uPA19 – 31 is depicted in Figure 1.
All four recombinant inhibitors (N-hTIMP-1-chCysWT,
N-hTIMP-3-chCysWT, N-hTIMP-1-chCys-uPA19 – 31, and
N-hTIMP-3-chCys-uPA19 – 31) were expressed in E. coli
cells (expression rate: approx. 10 – 15% of total protein).
The introduction of a His6-tag at the C-terminus allowed
purification of the recombinant proteins by use of Ni2 +-ni-
trilotriacetic acid affinity chromatography, yielding a puri-
ty of >95% under denaturing and reducing conditions
(Figure 1). The inhibitors contain structural and functional
important intramolecular disulfide bridges; therefore, the
purified proteins had to be refolded to obtain biologically
active proteins. The protocol used for refolding of
N-hTIMP-1-chCysWT and N-hTIMP-1-chCys-uPA19 – 31
(for details see Materials and Methods) was not suitable
for refolding of N-hTIMP-3-containing recombinant pro-
teins (more than 90% of the protein precipitated). After
testing different protocols for refolding of the N-hTIMP-3
variants, a modification of the method described by Ne-
gro et al. (1997) was used instead. The highest achiev-
able active concentration of any of the four purified re-
combinant proteins corresponded to only about 8% of
total protein. The reason for the low recovery of active in-
hibitors is very likely due to the presence of six disulfide
bridges in all four recombinant inhibitors (three in the N-
terminal domain of TIMP-1/-3 and three in chCys) that
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have to be correctly formed during the refolding process
(Magdolen et al., 2002). 
Inhibition of Matrix Metalloproteinases by
N-hTIMP-1- or N-hTIMP-3-Containing 
Recombinant Inhibitors
The inhibitory capacity of the TIMP-domains of the bi-
and trifunctional inhibitors was tested in MMP activity as-
says. A representative result is depicted in Figure 2. The
multifunctional inhibitors as well as recombinantly ex-
pressed, purified and refolded N-hTIMP-1 significantly
reduced the proteolytic activity of MMP-2. With heat-de-
natured inhibitors added to the wells as negative control
samples, inhibition was almost but not completely abol-
ished. The residual inhibitory activity may be due to re-
naturation of part of the inhibitors after heat-denatura-
tion. All multifunctional inhibitors and N-hTIMP-1 were
additionally analyzed in MMP-1 and MMP-9 assays and
were shown to reduce the activity of both matrix metallo-
proteinases by about 40 – 90% (data not shown).
The inhibitory capacity of the multifunctional inhibitors
toward MMP-2 was verified also by reverse zymography.
As shown in Figure 3, all inhibitors prevented degradation
of gelatin by MMP-2 in the gel matrix, leading to protein
staining of non-degraded gelatin at the expected posi-
tions of the inhibitors. These bands are not visible in the
control gel, which was loaded with the same amount of
inhibitors (approx. 0.25 µg) but did not contain gelatin
and MMP-2.
In addition to expression in E. coli, the trifunctional in-
hibitor N-hTIMP-1-chCys-uPA19 – 31 was also produced in
the eukaryotic baculovirus expression system. Secretion
of the recombinant protein by insect cells was directed
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Fig. 1 Structure of the Trifunctional Inhibitor N-hTIMP1-chCys-uPA19 – 31.
The cDNA sequence encoding the N-terminal domain of human TIMP-1 was fused to the DNA sequence encoding chCys-uPA19 – 31 and
cloned into the bacterial expression vector pQE-60. In a similar manner, the fusion genes encoding N-hTIMP-1-chCysWT, N-hTIMP-3-
chCysWT, and N-hTIMP-3-chCys-uPA19 – 31 were designed and generated. The inset displays SDS-PAGE analyses of extracts from E.
coli cells expressing the recombinant chimeric proteins (2 – 5) and the multifunctional inhibitors after affinity purification (6 – 9). Lane 1:
cell extract from recipient E. coli strain; lanes 2 and 6: N-hTIMP-1-chCysWT; lanes 3 and 7: N-hTIMP-3-chCysWT; lanes 4 and 8:
N-hTIMP-1-chCys-uPA19 – 31; lanes 5 and 9: N-hTIMP-3-chCys-uPA19 – 31.
Fig. 2 Activity of Recombinant Inhibitors as Tested by the Biotrak MMP-2 Activity Assay.
0.5 µg to about 2 µg of recombinant inhibitors were incubated with activated MMP-2 (6 ng/ml) overnight at 4°C. Then, the detection en-
zyme and chromogenic substrate were added and the residual MMP-2 activity was monitored in a spectrophotometer at 405 nm. As a
control, N-hTIMP-1-chCysWT and N-hTIMP-1-chCys-uPA19 – 31 were inactivated at 96°C for 10 min prior to incubation with activated
MMP-2 (hatched bars).The assays were performed in duplicate for each value. Standard deviations are not depicted, as they were usu-
ally less than 1%.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 12:01
by the natural human TIMP-1 presequence. The protein
was purified under native conditions and displayed in-
hibitory activity against all of the three tested MMPs
(MMP-1, -2, and -9) in MMP activity assays. In reverse zy-
mography analyses, this variant (N-hTIMP-1-chCys-
uPA19 – 31baculo) shows a slightly elevated apparent mo-
lecular mass (Figure 3). As it is produced in an eukaryotic
expression system, this is most probably due to glycosy-
lation of the TIMP-1 moiety (Brew et al., 2000).
Inhibition of the Cysteine Protease Papain 
The inhibitory activity of recombinant multifunctional in-
hibitors toward the cysteine protease papain was also
tested by reverse zymography (Figure 4). About 0.25 µg
of purified and refolded multifunctional inhibitors as well
as recombinant chCysWT were subjected to a 0.1% ca-
sein containing SDS polyacrylamide gel electrophoresis.
After removal of SDS, the gel was incubated in a buffer
containing papain, added to digest its substrate casein.
The bands on the Coomassie Blue-stained gel corre-
spond to non-degraded casein at the positions of
chCysWT (approx. 13 kDa) and multifunctional proteins
(approx. 31 kDa) (Figure 4A). A control gel lacking casein
was treated in the same way and showed no bands (Fig-
ure 4B). Again, the apparent molecular mass of N-hTIMP-
1-chCys-uPA19 – 31 produced in insect cells was slightly
increased as compared to the corresponding protein
synthesized by E. coli cells. 
In addition, the Ki values of the recombinant proteins
for papain were determined (Table 1). Recombinant
N-hTIMP-1-chCysWT, N-hTIMP-3-chCysWT, N-hTIMP-
1-chCys-uPA19 – 31, and N-hTIMP-1-chCys-uPA19 – 31bac-
ulo display Ki values close to that of natural chicken cys-
tatin from egg white, indicating that insertion of the
uPA-derived peptide (uPA19 – 31) as well as the presence of
the N-terminal domain of TIMP-1/-3 and the C-terminal
His6-tag have no negative influence on inhibitory activity
towards cysteine proteases.
Interaction of the Recombinant Inhibitors with Cell
Surface-associated uPAR
To investigate whether N-hTIMP-1-chCys-uPA19 – 31 (har-
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Fig. 3 Reverse Zymography Analyzing the Inhibitory Activity toward MMP-2.
(A) Approx. 0.25 µg of recombinant N-hTIMP-1-chCysWT (lane 1), N-hTIMP-1-chCys-uPA19 – 31 (lane 2), N-hTIMP-3-chCysWT (lane 3),
N-hTIMP-1-chCys-uPA19 – 31baculo (lane 4), N-hTIMP-3-chCys-uPA19 – 31 (lane 5), and N-hTIMP-1 (lane 6), respectively, were loaded into
wells of an SDS polyacrylamide gel containing gelatin plus MMP-2. After electrophoresis, SDS was removed from the gel and the gel
incubated overnight at 37°C in 50 mM Tris-HCl, pH 7.5, 5 mM CaCl2 and 5 µM ZnCl2 for the digestion of the MMP-2 substrate, gelatin.
Subsequently, the gel was stained with Coomassie Blue. (B) Control gel lacking gelatin and MMP-2.
Fig. 4 Reverse Zymography Analyzing the Inhibitory Activity toward Papain.
(A) About 0.25 µg of recombinant N-hTIMP-1-chCysWT (lane 1), N-hTIMP-3-chCysWT (lane 2), N-hTIMP-1-chCys-uPA19 – 31baculo
(lane 3), N-hTIMP-1-chCys-uPA19 – 31 (lane 4), N-hTIMP-3-chCys-uPA19 – 31 (lane 5), and chCysWT, respectively, were loaded into wells of
an SDS polyacrylamide gel containing casein. After electrophoresis, the gel was washed extensively to remove SDS and incubated in
a solution containing papain for the digestion of the casein substrate. Subsequently, the gel was stained with Coomassie Blue. (B) Con-
trol gel lacking casein.
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boring the uPAR-binding region of uPA) interacts with cell
surface-associated uPAR, phorbol 12-myristate 13-ac-
etate (PMA)-stimulated U937 cells were incubated with
fluorescently labeled high molecular weight uPA (FITC-
HMW-uPA) mixed with various concentrations of purified,
refolded N-hTIMP-1-chCys-uPA19 – 31, and the resulting
cell-associated fluorescence was determined. N-hTIMP-
1-chCysWT (lacking the uPAR-binding site) served as the
control protein. As shown in Figure 5, N-hTIMP-1-chCys-
uPA19 – 31 reduced binding of FITC-HMW-uPA to uPAR in a
dose-dependent manner whereas N-hTIMP-1-chCysWT
did not influence uPA/uPAR-interaction (Figure 5). The
IC50 value of ATF (approx. 15 kDa) was calculated to be
approx. 1.35 nM. In the case of N-hTIMP-1-chCys-
uPA19 – 31 (approx. 30 kDa), one has to consider that only
4% of the purified, refolded protein used in FACS analysis
was active (as tested by cystatin activity). Taking this into
account, the IC50 value (of the active protein) was about
6.7 nM, i.e. about 5-fold higher as that of the natural ligand
ATF.
Simultaneous Interaction of the Recombinant
Inhibitors with Papain and MMP-2
The capacity of multifunctional inhibitors to simultaneous-
ly interact with the cysteine proteases and MMPs was as-
sessed by surface plasmon resonance (SPR). For this, the
cysteine protease papain was covalently bound to a SPR-
sensor chip (CM-5). chCysWT, N-hTIMP-1-chCysWT, or
N-hTIMP-1-chCys-uPA19 – 31 was allowed to bind to the im-
mobilized papain (Figure 6A), followed by addition of acti-
vated MMP-2. MMP-2 bound only to the recombinant in-
hibitors harboring the N-terminal domain of TIMP-1, but
not to chCysWT (Figure 6B). Furthermore, different con-
centrations of activated MMP-2 were applied to the N-
hTIMP-1-chCys-uPA19 – 31/papain complex and a concen-
tration-dependent binding was observed (Figure 6C).
Similar data were obtained with N-hTIMP-1-chCysWT (not
shown). By applying the BIAcore evaluation software, the
binding constants for MMP-2 to the multifunctional in-
hibitor/papain complex were calculated: Kd [N-hTIMP-1-
chCys-uPA19 – 31] = 29.5 nM; Kd [N-hTIMP-1-chCysWT] =
32.0 nM. These values are in agreement with the Kd value of
activated MMP-2 to recombinant human TIMP-1 (Kd =
28.6 nM) previously reported by Olson et al. (1997).
Multifunctional Inhibitors of Tumor-Associated Proteolytic Systems 1089





chCys-uPA19 – 31b 1.9
N-hTIMP-1-chCysWT 2.0
N-hTIMP-1-chCys-uPA19 – 31 1.9
N-hTIMP-1-chCys-uPA19 – 31baculo 1.4
N-hTIMP-3-chCysWT 2.0
N-hTIMP-3-chCys-uPA19 – 31c n.d.
aThe inhibition constant for natural chCys was taken from Mach-
leidt et al. (1993).
bThe inhibition constants for recombinant chCysWT and chCys-
uPA19 – 31, respectively, were taken from Muehlenweg et al.
(2000).
cThe inhibition constant of N-hTIMP-3-chCys-uPA19 – 31 could
not be determined, because of a too low active concentration of
this inhibitor after refolding.
Fig. 5 Interaction of N-hTIMP-1-chCys-uPA19 – 31 with Cell Surface-Associated uPAR Determined by Flow Cytofluorometry (FACS). 
PMA-stimulated U937 cells were acid-washed to remove endogenous uPA. Then, cells were incubated with FITC-labeled HMW-uPA in
the presence of refolded N-hTIMP-1-chCys-uPA19 – 31 or N-hTIMP-1-chCysWT and, subsequently, binding of labeled uPA to cell sur-
face-associated uPAR was analyzed by flow cytofluorometry. N-hTIMP-1-chCysWT did not influence FITC-HMW-uPA binding, where-
as N-hTIMP-1-chCys-uPA19 – 31 significantly reduced uPA-binding to uPAR in a dose-dependent manner. The amino-terminal fragment
of uPA (ATF) served as a positive control.
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Expression of Multifunctional Inhibitors in Ovarian
Cancer OV-MZ-6#8 Cells
Ovarian cancer OV-MZ-6#8 cell lines were generated
which express and secrete the novel bi- and trifunctional
inhibitors. For this, the cells were stably transfected
with pRc-RSV-derived expression plasmids encoding ei-
ther pre-N-hTIMP-1-chCysWT, pre-N-hTIMP-1-chCys-
uPA19 – 31, pre-N-hTIMP-3-chCysWT, or pre-N-hTIMP-3-
chCys-uPA19 – 31. To prove synthesis and secretion of the
recombinant proteins, a sensitive ELISA (concentration
range: 0.25 to 32 ng/ml) was developed, which employs
a polyclonal antibody against recombinant chCysWT as
the catching antibody and a peroxidase-coupled mono-
clonal antibody directed against a His6-epitope as the de-
tection antibody (data not shown). All stably transfected
cell lines produced and secreted detectable amounts of
the respective multifunctional inhibitor into the medium,
with amounts ranging from 3 to 12 ng/ml secreted into
the medium after growth for 48 h. No reaction above the
ELISA background (medium only) was observed by test-
ing the conditioned medium of vector-transfected cells
(data not shown).
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Fig. 6 Simultaneous Interaction of the Recombinant Inhibitors with Papain and MMP-2 Tested by Surface Plasmon Resonance.
Approximately 2000 response units (RU) of papain were bound to a CM-5 chip inserted in the BIAcore 2000 system. Then, N-hTIMP-1-
chCys-uPA19 – 31, N-hTIMP-1-chCysWT, or chCysWT were injected for binding to papain. (A) Binding of N-hTIMP-1-chCys-uPA19 – 31 to
papain (arrow: start of injection, arrowhead: end of injection). Both, the rise and drop off of the reference unit signal is mainly due to the
change of buffer (bulk effect), whereas the difference in response (RU) before and after injection reflects the bound portion of chicken
cystatin variant to immobilized papain. The very slow dissociation is due to the tight interaction with a Ki value of about 2 pM (see Table 1)
and a low dissociation rate constant, koff =3.5×10– 5 s– 1, determined with the fluorogenic substrate Z-Phe-Arg-AMC from presteady-
state analysis (Machleidt et al., 1993). (B) Addition of activated MMP-2 to the papain-multifunctional inhibitor complexes results in bind-
ing to N-hTIMP-1-chCys-uPA19 – 31 (curve 3) and to N-hTIMP-1-chCysWT (curve 2), but not to chCysWT (curve 1); buffer bulk is not sub-
tracted. (C) Injection of different concentrations of activated MMP-2 (51, 68, and 102 µg/ml, curves 1 – 3, respectively) to the
papain-N-hTIMP-1-chCys-uPA19 – 31 complex; sensorgrams after subtraction of buffer bulk. Using these binding curves, the binding
constant for MMP-2 binding to the recombinant inhibitor was calculated.
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Biological Activity of Multifunctional Inhibitors in
Invasion Assays
To analyze the effects of the recombinantly expressed
multifunctional inhibitors on the invasive capacity of hu-
man ovarian cancer cells, we performed in vitro Matrigel
invasion assays. Stably transfected cells were placed
into the upper compartment of an invasion chamber on
top of a Matrigel-coated filter, the lower compartment
was filled with fetal calf serum (FCS)-containing medium
as a chemoattractant. After 48 h, the cells on the lower
side of the filter were counted. The results given in Fig-
ure 7A demonstrate that the inhibitor-producing cells ex-
hibit a significant decrease in invasion through Matrigel in
comparison to the vector-transfected control cells. A di-
rect quantitative comparison of the effectiveness of the
different inhibitors expressed by the ovarian cancer cells
is impossible, since (i) the cell clones produce varying
amounts of the recombinant inhibitors and (ii) the portion
of active recombinant protein is not known. In another set
of experiments, purified and refolded recombinant
N-hTIMP-1-chCysWT and N-hTIMP-1-chCys-uPA19 – 31,
produced in E. coli, were added exogenously to wild-type
OV-MZ-6#8 cells. Again, the inhibitors inhibited invasion
of the cancer cells through the Matrigel-coated filter
(Figure 7B). In these experiments, N-hTIMP-1-chCys-
uPA19 – 31 reduced tumor cell migration to a lower extent
than the bifunctional hybrid N-hTIMP-1-chCysWT, very
likely due to the fact that the active concentration of the
chCysWT-harboring fusion protein was much higher as
compared to the chCys-uPA19 – 31 variant (approx. 8%
versus approx. 4%).
Multifunctional Inhibitors of Tumor-Associated Proteolytic Systems 1091
Fig. 7 In vitro Matrigel Invasion Assays. 
(A) Stably transfected ovarian cancer OV-MZ-6# 8 cells were placed into the upper compartments of the invasion chambers (5×104 cells
in 500 µl 0.1% BSA/DMEM per insert). The lower chambers of the inserts were filled with 750 µl DMEM containing 10% FCS as the
chemoattractant. After 48 h incubation, the Matrigel layer plus noninvaded cells of the upper compartment was wiped off, the invaded
cells on the lower side of the filter were fixed, stained, and counted. Assays were performed in triplicate. Statistical differences relative
to the control pRc-RSV cells are denoted as (*), p<0.001 (Mann-Whitney U-test). (B) Invasion assays with recombinant purified and re-
folded inhibitors isolated from E. coli. Wild-type OV-MZ-6# 8 cells (5×104 cells in 400 µl) were applied to each upper compartment and
recombinant inhibitors (approx. 50 µg protein in 150 µl DMEM) were added to the cells together with 500 µg BSA. The controls received
PBS with 500 µg BSA. The diagram depicts results of one representative experiment performed in triplicate.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 12:01
Discussion
An important step in tumor invasion and metastasis is the
degradation of extracellular matrix, allowing cells to mi-
grate through connective tissue and basement mem-
branes. These processes involve the action and interac-
tion of several different proteolytic systems such as
cysteine proteases, serine proteases, and MMPs. In vivo,
all of these protease systems are controlled by specific
natural inhibitors, e.g. MMPs by the TIMP-family and ex-
tracellular cysteine proteases by cystatin C (for reviews
see Kos and Lah, 1998; Andreasen et al., 2000; Johans-
son et al., 2000; Stamenkovic, 2000; Ellis and Murphy,
2001; Magdolen et al., 2002). Due to the essential role of
proteolytic systems in tumor invasion and metastasis,
synthetic inhibitors were developed to be used as thera-
peutic agents to affect tumor progression (Sperl et al.,
2001; Coussens et al., 2002). All of these natural and syn-
thetic inhibitors are directed against only one of the men-
tioned protease systems. Thus, a promising strategy in
tumor therapy is to apply multifunctional inhibitors, which
reduce the activity of several or all of these protease sys-
tems involved in tumor progression.
Based on this idea a novel bifunctional inhibitor chCys-
uPA19 – 31 was developed by us (Muehlenweg et al., 2000)
which reduces the activity of cysteine proteases, such as
cathepsin B and L, and simultaneously also prevents
binding of uPA to its receptor uPAR. In this study we have
extended this strategy and have described the design
and generation of additional multifunctional inhibitors,
N-hTIMP-1-chCysWT, N-hTIMP-1-chCys-uPA19 – 31, N-
hTIMP-3-chCysWT, and N-hTIMP-3-chCys-uPA19 – 31,
which interfere with the MMP and cysteine protease sys-
tem, and in the case of uPA19 – 31-containing inhibitors
also with the uPA system. These recombinant bi- and tri-
functional inhibitors were expressed in E. coli and puri-
fied in an active conformation. In preparations of fusion
proteins harboring the chCys-uPA19 – 31-moiety, generally,
a smaller amount of active protein was present compared
to chCysWT-containing molecules, probably due to a
less effective refolding of the active, native structure.
Therefore, cloning and expression of the trifunctional in-
hibitor N-hTIMP-1-chCys-uPA19 – 31 was additionally per-
formed under native conditions in the eukaryotic bac-
ulovirus expression system. In fact, using this approach,
higher amounts of this inhibitor in active form was isolat-
ed using the baculovirus system as compared to the E.
coli system. This variant displays a slightly elevated ap-
parent molecular mass most probably due to glycosyla-
tion of the TIMP-1 moiety (Brew et al., 2000).
Quantitative evaluation of the inhibitory capacities of
the recombinant inhibitors demonstrated that the individ-
ual inhibitory domains are similarly potent as their natural
counterparts: (i) the Ki values (1.4 pM-2 pM) of the in-
hibitors against the cysteine protease papain are very
close to the inhibition constant (1.4 pM) of natural wild-
type cystatin (Machleidt et al., 1993). (ii) The binding affin-
ity of the TIMP-variants to MMP-2 as tested by SPR (Kd of
about 30 nM) is also similar to that of TIMP-1 with MMP-2
(Olson et al., 1997). (iii) The binding affinity of uPA19 – 31-
containing cystatin variants toward uPAR is in the range
of uPA binding to uPAR when analyzed by SPR (5 nM ver-
sus 17 nM; Muehlenweg et al., 2000). These results
strongly indicate that in the bi- and trifunctional inhibitors
the functional integrity of each individual module is not
significantly affected when recombinantly fused together.
Thus, these multifunctional inhibitors may represent suit-
able tools to efficiently inhibit members of either of the
three targeted protease families.
We have previously demonstrated that the bifunctional
inhibitor chCys-uPA19 – 31 inhibits cysteine proteases and
at the same time interferes with uPA/uPAR-interaction
(Muehlenweg et al., 2000). The same is true for the novel
bi- and trifunctional inhibitors with respect to interaction
with cysteine proteases and MMPs as shown by surface
plasmon resonance technology. Although the multifunc-
tional inhibitors have the capacity to simultaneously in-
hibit more than one of their target molecules, it is not im-
perative that a single trifunctional inhibitor can inhibit all
three target molecules at the same time. Rather, it is only
important that each molecule carries the potential to in-
hibit one of the three systems. The functions of the vari-
ous proteolytic systems may overlap or even be redun-
dant, as indicated by the apparent phenotype of
knockout mice deleted for these proteolytic factors
(Carmeliet and Collen, 1998). Therefore, the application
of multifunctional inhibitors is expected to be more effi-
cient as compared to therapeutic molecules with in-
hibitory activity against a single system only.
The analyses of the inhibitory capacity of the multi-
functional inhibitors in in vitro invasion assays, both by
use of transfected cancer cells endogenously producing
and releasing the inhibitors and by exogenous addition of
the recombinant proteins, demonstrated that the in-
hibitors do considerably reduce invasion of ovarian can-
cer cells. The characterization of recombinant purified in-
hibitors, although clearly demonstrating their inhibitory
activity, was hampered by the fact that a high percentage
of the purified proteins was inactive (in most cases due to
misfolding by the refolding procedure after expression in
E. coli, which was only partially improved by soluble ex-
pression with the baculovirus system). Therefore, the ap-
proach of exogenously applying recombinantly pro-
duced, purified inhibitors as therapeutic molecules in
cancer treatment seems to be rather unattractive. How-
ever, the endogenous (relatively low) expression of the in-
hibitors by transfected ovarian cancer cells showed a
dramatic effect on in vitro invasion, indicating that a ther-
apeutic approach employing e.g. viral vectors or other
gene transfer systems may be feasible to affect tumor
cell invasion. The very small size of our compact thera-
peutic molecules carrying up to three different inhibitory
functions may prove beneficial for generating appropriate
vectors, especially, if e.g. cell type-specific expression is
aspired, where rather large regulatory promoter se-
quences are used. Finally, one has also to consider that
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the introduction of any new inhibitory agent in cancer
therapy may be easier to achieve with only one therapeu-
tic molecule carrying multiple functions than with e.g.
three individual inhibitors.
In summary, the functional characterization of the mul-
tifunctional proteins presented here provides the basis
for analyses of the inhibitory capacities of the bi- and tri-
functional inhibitors in vivo. In fact, in a recent study the
effects on tumor growth and spread of ovarian cancer
cells in nude mice endogenously expressing the in-
hibitors versus vector controls were analyzed (Krol et al.,
2003). The recombinant proteins could be detected in as-
citic fluid and in tumor tissue indicating stable production
of the therapeutic molecules. Most importantly, in the
case of inhibitor-producing cell lines, a distinct reduction
of the tumor mass was observed, which demonstrates
sufficient concentrations of the inhibitors over time to
achieve a therapeutic effect. Thus, these novel bi- and tri-
functional inhibitors represent candidates for the explo-
ration of new therapeutic approaches in cancer patients,
e.g. via delivery of the genes encoding the therapeutic
molecules by viral or nonviral vector systems (Monahan
and Samulski, 2000; Scherer et al., 2002).
Materials and Methods
Generation of Expression Vectors Encoding Bi- and
Trifunctional Inhibitors
The cDNAs encoding human TIMP-1, human TIMP-3 (both kind-
ly provided by A. Krüger, Institut für Experimentelle Onkologie
und Therapieforschung, TU München, Germany), as well as
chicken cystatin (chCysWT; Muehlenweg et al., 2000) were used
as templates for multiple PCR amplification steps to generate
genes encoding bifunctional inhibitors. For synthesis of genes
encoding trifunctional inhibitors, the cDNA encoding chCys-
uPA19 – 31 was used, a cystatin variant, that harbors the uPAR-
binding site of the uPA molecule (Muehlenweg et al., 2000).
The coding regions of the N-terminal domains of TIMP-1
[amino acids (aa) 1 – 128] and TIMP-3 (aa 1 – 123) were fused to
the coding regions of chCysWT (aa 1 – 115) and of chCys-
uPA19 – 31 consisting of 117 aa. Between the two inhibitor do-
mains, a stretch of 10 aa was introduced as a flexible linker. The
constructs were inserted into the multiple cloning site of the E.
coli expression vector pQE-60 (Qiagen, Hilden, Germany) which
provides a C-terminal His6-tag. The recombinant plasmids were
transformed into cells of the E. coli strain M15 (pREP4). 
For generation of eukaryotic expression plasmids, again a
two-step cloning strategy was applied: (i) the pQE-60-derived
plasmids encoding the various bi- and trifunctional inhibitors
were used as templates for PCR amplification of the cystatin-en-
coding part including the N-terminally located flexible linker and
the C-terminal His6-tag. These fragments were directionally sub-
cloned into the eukaryotic expression vector pRc-RSV. (ii) The
coding regions of the N-terminal domains of TIMP-1 (aa 1 – 128)
plus its N-terminally located signal sequence consisting of 23 aa
and TIMP-3 (aa 1 – 123) plus its native signal sequence (23 aa),
respectively, were amplified and inserted 5’ of the cystatin vari-
ant-encoding sequences. The deduced aa sequences of the
mature recombinant fusion proteins (expressed by eukaryotic
cells) are identical to those of the proteins expressed in E. coli.
For expression in insect cells, the synthetic gene encoding
preN-hTIMP-1-chCys-uPA19 – 31 was ligated into the HindIII sites
of the transfer vector pBac2x (modified pBac4x-1, Novagen; P.
Rettenberger, unpublished), downstream of the polyhedrin pro-
moter.
In all cases, in the expression vectors the correct orientation
and sequence of the cloned DNA was verified by sequencing
(TopLab, Martinsried, Germany). 
Bacterial Expression, Purification and Refolding of
Multifunctional Inhibitors
E. coli clones were grown in LB Medium supplemented with
100 µg/ml ampicillin and 25 µg/ml kanamycin until an OD600 of
0.8 – 0.9, and subsequently expression of the recombinant pro-
tein was induced for 5 h by addition of isopropyl-ß-D-thiogalac-
topyranoside (IPTG; final concentration 2 mM). Purification of the
proteins was performed under denaturing and slightly reducing
conditions. The bacterial cells were harvested by centrifugation
and then lysed in 6 M guanidine hydrochloride (GuHCl), 100 mM
NaH2PO4, 10 mM Tris-HCl, pH 8.0, 8 mM β-mercaptoethanol by
gently shaking for 2 h at room temperature (RT). The cell debris
was removed by centrifugation and the supernatant subjected
to Ni2 +-nitrilotriacetic acid (NTA)-agarose affinity chromatogra-
phy. After four washing steps, first with 6 M GuHCl, 100 mM
NaH2PO4, 8 mM β-mercaptoethanol, 10 mM Tris-HCl, pH 8.0 and,
subsequently, with 8 M urea, 100 mM NaH2PO4, 8 mM β-mercap-
toethanol, 100 mM Tris-HCl (pH 8.0, pH 7.0, and pH 6.3, respec-
tively), the proteins were eluted with this buffer but at pH 4.1. For
refolding of N-hTIMP-1-chCysWT and N-hTIMP-1-chCys-
uPA19 – 31, dithiothreitol (DTT) was added at a final concentration
of 50 mM and the proteins were dialyzed against 6 M urea, 0.02%
NaN3, 50 mM Tris-HCl, pH 8.0, for 8 h at RT, followed by two dial-
ysis steps at 4°C each for 48 h against 2 M urea, 300 mM NaCl,
2.5 mM reduced glutathione, 0.5 mM oxidized glutathione,
0.02% NaN3, 50 mM Tris-HCl, pH 8.0, and one dialysis step
against phosphate buffered saline (PBS), pH 7.4, for 24 h. For
refolding of N-hTIMP-3-chCysWT and N-hTIMP-3-chCys-
uPA19 – 31, a modification of the method described by Negro et al.
(1997) was used. Briefly, 2 ml of Ni2 +-NTA resin and β-mercap-
toethanol to a final concentration of 8 mM were added to 1 mg of
eluted protein. The protein solution was gently shaken for 2 h at
RT and then dialyzed against 100 mM sodium phosphate,
pH 8.3, for 3 d at 4°C. The refolded protein was eluted from the
resin with 8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 4.1,
and then dialyzed against PBS, pH 7.4, for 24 h. Refolded pro-
teins were stored in aliquots at – 20°C until use.
Production of the Trifunctional Inhibitor 
N-hTIMP-1-chCys-uPA19 – 31 in Insect Cells
Spodoptera frugiperda Sf21 cells were routinely maintained in
TC100 medium (Gibco, Pailsley, UK) supplemented with 10%
foetal calf serum (FCS) and Sf9 cells in Sf900II serum-free medi-
um (Gibco) at 28°C. BacPAK6∆chi (L. A. King, unpublished), a
mutant of the autographa californica multiple nucleopolyhe-
drovirus (AcMNPV) variant BacPAK6 (Kitts and Possee, 1993)
lacking the chitinase gene (Thomas et al., 1998; Possee et al.,
1999) was used as baculovirus vector.
Cotransfection was performed essentially as previously
described (King and Possee, 1992). Briefly, adherend Sf21 were
incubated with a mixture of Bsu36I-digested BacPAK6∆chi,
transfer vector pBac2x-preN-hTIMP-1-chCys-uPA19 – 31, and
Lipofectin™ (Gibco) in serum-free TC100. After overnight incu-
bation, the medium was replaced with TC100 supplemented
with 10% FCS and harvested after 3 d of further incubation. To
identify recombinant virus the cell supernatant was screened in
a plaque assay with lacZ as genetic marker for the wild-type
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virus vector (Kitts and Possee, 1993). The amplification of re-
combinant virus was performed in suspension cultures of Sf9
cells as previously described (King and Possee, 1992). 
For protein production, suspension cultures of 2×106 Sf9
cells/ml were infected at a multiplicity of infection (m.o.i.) of 2 or
mock-infected, and harvested after 48 h post-infection. The cell
supernatant was collected after centrifugation at 1000 g for
10 min at 4°C, and then analysed by Western blot using INDIA™
HisProbe-HRP (Pierce, Tattenhall, UK) to detect the recombinant
hexahistidine-tagged protein. The supernatant was subjected to
Ni2 +-affinity chromatography (Chelating Sepharose; Amersham
Pharmacia Biotech, Little Chalford, UK). After the column was
washed three times with 50 mM imidazole, 500 mM NaCl, pH 7.0,
at 4°C, the recombinant protein was eluted with 450 mM imida-
zole, 500 mM NaCl, pH 7.0, at 4°C. Peak fractions were pooled
and dialyzed against PBS, pH 7.4, for 24 h. The purity of the elut-
ed recombinant protein was assessed by SDS polyacrylamide
gel electrophoresis followed by Coomassie Blue staining and
the concentration determined using the Bradford protein assay
(Bio-Rad, Hemel Hempstead, UK) and then stored at – 20°C un-
til use.
Stable Transfection of OV-MZ-6#8 Cells
OV-MZ-6#8 cells (Fischer et al., 1998; Lutz et al., 2001) were
transfected in the presence of Lipofectin™ (Gibco, Karlsruhe,
Germany) with the various eukaryotic expression plasmids 
(pRc-RSV-N-hTIMP-1-chCysWT; pRc-RSV-N-hTIMP-1-chCys-
uPA19 – 31; pRc-RSV-N-hTIMP-3-chCysWT; pRc-RSV-N-hTIMP-
3-chCys-uPA19 – 31) and stably transfected cells were isolated
upon G418 (geneticin) selection. Transfections with the empty
vector pRc-RSV served as a control. 
For detection and quantification of the recombinant multi-
functional inhibitors, a sandwich ELISA format was developed in
a similar fashion as described previously (Kotzsch et al., 2000).
For this, rabbit polyclonal antibodies directed against purified re-
combinant chCysWT produced in E. coli (Muehlenweg et al.,
2000) were generated (Pineda Antikörperservice, Berlin, Ger-
many) and used as the catcher antibody. As the detecting anti-
body, a mouse monoclonal antibody directed to the histidine-tag
(Penta-His) coupled to peroxidase (Qiagen) was applied. Serial
dilutions of recombinant chCysWT in sample buffer, covering a
concentration range of 0.25 to 32 ng/ml, served as standard.
MMP Activity Assays 
The inhibitory activity of the recombinant bi- or trifunctional in-
hibitors was tested in MMP-1, -2, and -9 activity assays (Bio-
trak™; Amersham Biosciences, Freiburg, Germany). The assay
buffer contained 50 mM Tris-HCl, pH 7.6, 1.5 mM NaCl, 0.5 mM
CaCl2, 1 µM ZnCl2, 0.01% (v/v) Brij™ 35, 0.01% (w/v) gelatin
(only in the MMP-2 assay) and 500 µg/ml of bovine serum albu-
min (BSA). Fifty µl of enzyme (MMP-2: 6 ng/ml; MMP-1:
25 ng/ml; MMP-9: 8 ng/ml) were activated with 50 µl of 0.5 mM
p-aminophenylmercuric acetate (APMA) for 15 min at 37 oC.
Then, inhibitors (0.5 – 2 µg in 10 to 40 µl) were added and incu-
bated for 20 min at RT, and, finally, the microtiter plate of the var-
ious MMP-assays was incubated overnight at 4°C. As negative
control, a mixture without MMPs was used; as a positive con-
trols, MMPs were incubated with PBS instead of inhibitors, or
heat-denatured (10 min at 95°C) inhibitors were used. 
The next day, the plates were washed four times (10 mM sodi-
um phosphate, pH 7.0, 0.05% Tween 20). One hundred µl of de-
tection reagent (consisting of detection enzyme and chro-
mogenic substrate) were added to each well and the resulting
color changes at 405 nm were monitored over several hours in a
spectrophotometer. 
Reverse Zymographic Analyses
The inhibitory activity of recombinant trifunctional inhibitors
against the cysteine protease papain was tested by reverse zy-
mography. A 15% SDS polyacrylamide minigel containing 0.1%
(w/v) casein and a control gel without casein were prepared. The
inhibitor samples (approx. 0.25 µg) were loaded in nonreducing
sample buffer into the wells of these gels and electrophoresis
was performed. After electrophoresis, gels were washed in 2.5%
Triton X-100 three times for 30 min at RT and then incubated in
100 mM phosphate buffer, pH 6.0, containing 2 mM cysteine,
1 mM EDTA, and 0.01 mg/ml papain (40°C for 2.5 h). Thereafter
the gels were stained with 0.05% Coomassie Brilliant Blue in
40% ethanol/10% acetic acid solution overnight and destained
in 35% ethanol/10% acetic acid for 3 h.
The inhibitory activity of recombinant bi- and trifunctional in-
hibitors against MMP-2 was also tested by reverse zymography.
Minigels were prepared containing 12.5% SDS polyacrylamide,
1 mg/ml gelatin, 0.5 µg/ml MMP-2 (Roche, Penzberg, Germany).
The inhibitor samples (approx. 0.25 µg) each in nonreducing
sample buffer were loaded and electrophoresis was performed
with 15 mA at 4°C. After electrophoresis, the gels were washed
in 50 mM Tris-HCl, pH 7.5, 5 mM CaCl2, 5 µM ZnCl2, 2.5% Triton
X-100 (3 h, 37°C) with three buffer changes. Incubation was per-
formed in 50 mM Tris/HCl, pH 7.5, 5 mM CaCl2, 5 µM ZnCl2,
0.02% NaN3 at 37°C overnight. After fixation in 40%
ethanol/10% acetic acid for 10 min, the gels were stained with
0.5% Coomassie Blue in 35% ethanol/10% acetic acid for at
least 2 h and destained in 35% ethanol/10% acetic acid. A con-
trol gel without gelatin and without MMP-2 was run and stained
as well.
Determination of Kinetic Constants and Active
Concentrations
To determine the inhibitory activity of the multifunctional in-
hibitors toward cysteine proteases continuous fluorimetric inhi-
bition assays were performed and evaluated as described previ-
ously (Muehlenweg et al., 2000).
Flow Cytofluorometry
U937 cells were stimulated with 1 mM (final concentration) of
phorbol-12-myristate-13-acetate-4-O-methyl ether (Sigma-
Aldrich, Taufkirchen, Germany) for 72 h at 37°C. After washing
with PBS, the cells were incubated with 50 mM glycine/100 mM
NaCl, pH 3.0, for 1 min at RT to dissociate endogenous receptor-
bound uPA and then the acidic buffer was neutralized with an
equal volume of 500 mM HEPES/100 mM NaOH, pH 7.5. After
washing, the cells were resuspended in PBS/0.1% BSA (107
cells/ml) and then 2.5×105 cells were incubated for 30 min with a
mixture of fluorescein isothiocyanate (FITC)-labeled high molec-
ular weight (HMW) uPA (16 ng) plus different concentrations of
refolded multifunctional inhibitors or the amino terminal frag-
ment of uPA (ATF). Cell-associated fluorescence was deter-
mined by flow cytofluorometry (Muehlenweg et al., 2000).
Surface Plasmon Resonance Analysis
Simultaneous interaction of the recombinant inhibitor proteins
with the cysteine protease papain and MMP-2 was followed by
real time analysis utilizing the BIAcore 2000 system (BIAcore AB,
Uppsala, Sweden). All experiments were performed at 25°C at a
flow rate of 5 µl/min. Papain was immobilized to a CM-5 chip us-
ing the amino-coupling kit according to the manufacturer’s rec-
ommendation. Then, 200 µl of N-hTIMP-1-chCysWT or N-
hTIMP-1-chCys-uPA19 – 31 or chCysWT (final concentration
50 µg/ml) in HBS-P-BSA buffer [10 mM HEPES, pH 7.4, 150 mM
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NaCl, 0.005% (v/v) Tween 20, 0.05% BSA] were applied to the
papain-coupled chip to form a papain-cystatin complex. After
intensive washing, 110 µl of different concentrations (51, 68, and
102 µg/ml) of MMP-2 (Roche), activated by p-aminophenylmer-
curic acetate (APMA) (30 min at 37°C), were injected to follow
the formation of the ternary papain-[N-hTIMP-1-cystatin(vari-
ant)]-MMP-2 complex. Regeneration was achieved by injection
of HBS-EP puffer [10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005%
(v/v) Tween 20, 3 mM EDTA]. The association and dissociation
constants of the interaction of MMP-2 with the N-hTIMP-1-
chCys-uPA19 – 31 and N-hTIMP-1-chCysWT were determined us-
ing the BIA evaluation software of BIAcore.
Cell Invasion Assays
Invasion assays were performed according to Szpaderska and
Frankfater (2001). Aliquots of Matrigel (11.3 mg/ml, Becton Dick-
inson Labware, Bedford, USA) were stored frozen at – 20°C. Af-
ter thawing on ice overnight the Matrigel was diluted 1:24 with
cold PBS and the membrane inserts (6.4 mm diameter, 8 µm
pores; Becton Dickinson Labware) for 24-well plates were coat-
ed with 60 µl Matrigel per insert (density of 85 µg/cm2). The
plates were incubated for 3 h at 37°C in a cell culture incubator.
After gelling the Matrigel was dried overnight in uncovered
plates in a laminar hood. The next day, the gel was rehydrated for
2 h by addition of 200 µl serum-free Dulbecco`s Modified Eagle
Medium (DMEM)/0.1% BSA. Transfected cells were grown until
60 to 80% confluence was reached and adjusted to 105 cells/ml
DMEM/0.1% BSA. 5×104 transfected cells/500 µl medium were
seeded into each insert. The lower chambers of the inserts were
filled with 750 µl DMEM containing 10% FCS as a chemoattrac-
tant. For every value, assays were performed in triplicate. After
48 h of incubation the Matrigel with the noninvaded cells was
wiped off with a tissue and invaded cells on the lower side of the
filter were fixed and stained (Diff-Quick®, Dade Behring AG,
Switzerland). The stained cells were counted under the micro-
scope (100× magnification) with the help of a grid. 
Cell invasion assays with recombinant inhibitors isolated from
E. coli or the baculovirus system were performed similarly. Wild-
type OV-MZ-6# 8 cells (5×104 cells) in 400 µl DMEM were applied
to each insert and recombinant inhibitors (up to 50 µg inhibitor
protein in 150 µl) were added to the cells together with 500 µg
BSA. Controls received PBS with 500 µg BSA. As another con-
trol, heat-denatured inhibitors (10 min at 95°C) were used. The
invasion was stopped after 24 h of incubation and the level of
cell invasion was detected as described above.
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